Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Mon, 04th May 2020 14:35

(Alliance News) - Open Orphan PLC on Monday announced that Chief Executive Trevor Phillips will be standing down and said it has signed a new contract with a US biotechnology.

Shares in the pharmaceutical services firm were up 10% at 9.90 pence in London in afternoon trading.

Philips will stay in his role until June end but has departed the board with immediate effects. He joined hVIVO at the end of 2018 and led hVIVO's merger with Open Orphan. Executive Chair Cathal Friel will lead Open Orphan.

The new contract is for Open Orphan to provide a human challenge study in respiratory syncytial virus, a highly contagious viral disease and among the most common causes of pneumonia and bronchiolitis. Challenge studies purposefully expose healthy volunteers to an infectious disease.

The biotechnology company's name was not disclosed, though Open Orphan expects to receive around GBP3.5 million of revenue in 2020 from the study.

Open Orphan acquired Venn Life Sciences Holdings PLC in January, the same month its completed its merger with hVIVO PLC. The study will use the clinical research organisation services of hVIVO and Venn and will take place at hVIVO's London-based quarantine unit in the third quarter of 2020.

Friel said: "Firstly, I would like to thank Trevor for his help merging Open Orphan and hVIVO. Trevor had previously successfully right sized and focused hVIVO and our refreshed management team is now focused on delivering growth at a very exciting time for the company.

"The signing of this new GBP3.5 million contract with a US biotechnology company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts. Open Orphan will be utilising its complementary in-house [clinical research organisation] services of hVIVO and Venn to deliver this contract. This contract demonstrates the Open Orphan and hVivo group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reduce costs."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
11 Nov 2019 16:29

Open Orphan inks preferred partner deal with Ipsen Group

(Sharecast News) - Europe-focussed rare and orphan drug consulting services platform Open Orphan announced the signing of a preferred partner agreement with Ipsen Group on Monday.

Read more
11 Nov 2019 13:48

Open Orphan Inks Venn Life Preferred Partner Agreement With Ipsen

Open Orphan Inks Venn Life Preferred Partner Agreement With Ipsen

Read more
15 Oct 2019 13:11

Open Orphan Inks Health Data Platform Deal With Empiric Logic

Open Orphan Inks Health Data Platform Deal With Empiric Logic

Read more
15 Oct 2019 11:13

Open Orphan signs deal with Empiric Logic to complete Health Data platform

(Sharecast News) - Europe-focussed rare and orphan drug consulting services platform provider Open Orphan has signed a new strategic collaboration agreement with Empiric Logic, it announced on Tuesday, to build on the earlier work it had performed, and complete the build out of its 'Health Data' platform as Europe's first rare disease, advocacy-led genomic database.

Read more
25 Sep 2019 11:51

Open Orphan Loss Widens On Venn Life Sciences Combination Cost

Open Orphan Loss Widens On Venn Life Sciences Combination Cost

Read more
1 Aug 2019 17:37

Open Orphan Names Ex-Horizon Therapeutics Director As Non-Executive

(Alliance News) - Drug consulting platform Open Orphan PLC said on Thursday that it has appointed David Kelly as an independent non-executive director.Kelly, the company said, has orphan in

Read more
12 Jul 2019 11:57

Open Orphan Divests Remaining 3.1% Stake In Integumen

(Alliance News) - Open Orphan PLC has netted over GBP500,000 after selling the rest of its shares in skin-care firm Integumen PLC, Open Orphan said on Friday.The sale of the 30.1 million on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.